Table 1.

Key Inclusion Criteria for the Placebo-Controlled Trials

Study	Treatment Arm	N	Age Range (Years)	Duration of Current MDE	MADRS Total Score
NCT00635219 (11984A)36	Placebo	145	18–75	≥3 months	≥26
	Vortioxetine 5 mg/day	155
	Vortioxetine 10 mg/day	151
NCT01140906 (13267A)37	Placebo	158	18–75	≥3 months	≥26
	Vortioxetine 15 mg/day	149
	Vortioxetine 10 mg/day	152
NCT00672958 (303)38	Placebo	286	18–75	≥3 months	≥30
	Vortioxetine 5 mg/day	292
NCT00672620 (304)39	Placebo	149	18–75	≥3 months	≥22
	Vortioxetine 5 mg/day	153
NCT00735709 (305)40	Placebo	139	18–75	≥3 months	≥26
	Vortioxetine 5 mg/day	139
	Vortioxetine 10 mg/day	139
NCT01153009 (315)41	Placebo	153	18–75	≥3 months	≥26
	Vortioxetine 15 mg/day	145
	Vortioxetine 20 mg/day	147
NCT01163266 (316)42	Placebo	155	18–75	≥3 months	≥26
	Vortioxetine 10 mg/day	155
	Vortioxetine 20 mg/day	148
NCT01179516 (317)43	Placebo	149	18–75	≥3 months	≥26
	Vortioxetine 10 mg/day	143
	Vortioxetine 15 mg/day	142
NCT01255787 (CCT-002)44	Placebo	150	20–64	≥3 months	≥26
	Vortioxetine 5 mg/day	144
	Vortioxetine 10 mg/day	147
	Vortioxetine 20 mg/day	149
NCT01355081 (CCT-003)45	Placebo	124	20–75	≥3 months	≥26
	Vortioxetine 15 mg/day	119
	Vortioxetine 20 mg/day	122
NCT02389816 (CCT-004)46	Placebo	161	20–75	≥3 months	≥26
	Vortioxetine 10 mg/day	165
	Vortioxetine 20 mg/day	163

Abbreviations: MADRS, Montgomery–Åsberg Depression Rating Scale; MDE, major depressive episode.